Ali Akbar Hafezi - Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
Sajjad Ghaffari - Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
Jamshid Abedi - Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
Jalal Taherian - Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Fars, Iran

Introduction: Patients with breast cancer with different molecular subtypes may have different pathological responses to neoadjuvant chemotherapy (NAC). The aim of this study was to evaluate the pathological response to NAC in patients with locally advanced breast cancer based on molecular subtypes. Materials and Methods: In this retrospective cohort study, 210 female patients with breast cancer candidate for NAC referred to the radiation oncology departments in northern Iran between August 2013 and September 2018 were evaluated in terms of pathologic complete response (pCR) based on immunohistochemical molecular markers (estrogen and progesterone receptors, Her-2/neu and Ki-67), overall survival (OS) and disease-free survival (DFS). Results: The mean age of the patients was 38.22 ± 10.34 years and 68 patients (32.4%) had a positive family history of breast cancer. The pCR rate was 17.6% (37 patients), which in the subtypes of luminal A, luminal B, Her-2/neu positive and triple negative was 7.7%, 16.9%, 26.5% and 21.05%, respectively. Patients with pCR had significantly better OS (78.4% vs. 49.1%, P = 0.014) and DFS (83.8% vs. 51.4%, P = 0.020) than patients with partial/no pathologic response. Conclusion: It seems that molecular subtype plays a decisive role in the clinical outcome and the pathologic response to NAC in patients with locally advanced breast cancer.

Locally Advanced Breast Cancer, Neoadjuvant Chemotherapy, Pathologic Complete Response